NRAS and myelodysplastic syndrome: Furthermore, mutations in genes involved in signaling pathways like FLT3, KIT, KRAS, NRAS might be sub-clonal and have a low negative predictive value, according to 2021 and 2024 ELN updates for MDS and AML, even though they could indicate the presence of residual AML cells.